ATLANTA, GA – – (ACCESSWIRE – December 29, 2022) – – Holzer & Holzer, LLC is investigating whether Design Therapeutics, Inc. (“Design Therapeutics” or the “Company”) (NASDAQ: DSGN) complied with federal securities laws. On December 7, 2022, Design Therapeutics announced initial results from the Company’s Phase 1 clinical trial in patients with Friedreich ataxia. As part of the initial results, the Company disclosed that “16 (73%) patients on DT-216 and eight (73%) patients on placebo reported at least one treatment-emergent adverse event.” Following this disclosure, the Company’s stock price dropped.
If you purchased Design Therapeutics stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at email@example.com or Joshua Karr, Esq. at firstname.lastname@example.org, call our toll-free number at (888) 508-6832, or visit our website https://holzerlaw.com/case/design-therapeutics/ to discuss your legal rights.